Insider Trading March 12, 2026

Doximity interim PFO sells Class A stock worth $58,833; firm posts beat amid mixed analyst views

Sitaram Siddharth executed an automatic sale under a 10b5-1 plan, converted Class B shares and exercised options as the company reported stronger-than-expected quarterly results

By Priya Menon DOCS
Doximity interim PFO sells Class A stock worth $58,833; firm posts beat amid mixed analyst views
DOCS

Interim principal financial officer and principal accounting officer Sitaram Siddharth sold 2,319 shares of Doximity Class A common stock on March 10, 2026, through an automatic Rule 10b5-1 plan for proceeds of $58,833. On the same day he converted 5,000 Class B shares into Class A shares and exercised 5,000 options at a $4.12 strike. Doximity’s shares are trading near their 52-week low and have fallen 66% over six months, even as the company posted fiscal third-quarter revenue and EBITDA above guidance and consensus; analysts have issued a range of reactions on price targets and ratings.

Key Points

  • Interim PFO Sitaram Siddharth sold 2,319 Class A shares under a Rule 10b5-1 plan for $58,833 and converted 5,000 Class B shares to Class A while exercising 5,000 options at $4.12.
  • Doximity reported fiscal Q3 revenue and EBITDA that exceeded guidance and consensus by $4.6 million and $7.9 million, respectively.
  • Analysts reacted variably: Canaccord upgraded to Buy but lowered its target to $34.00; Piper Sandler raised its target to $42.00 and kept Overweight; Mizuho and BMO cut targets to $34.00 and $25.00, respectively.

Transaction details

Sitaram Siddharth, serving as interim principal financial officer and principal accounting officer of Doximity, Inc. (NASDAQ:DOCS), sold 2,319 shares of Class A Common Stock on March 10, 2026. The shares were sold at $25.37 each for total gross proceeds of $58,833. The disposition occurred automatically under a Rule 10b5-1 trading arrangement.


Share-class conversions and option exercise

Also on March 10, Siddharth converted 5,000 shares of Class B Common Stock into Class A Common Stock. In addition, he acquired 5,000 shares through the exercise of stock options carrying an exercise price of $4.12.


Market context and valuation signals

At the time reporting the transaction, Doximity shares were trading at $24.28, slightly above the company’s 52-week low of $23.53. According to analysis cited in the report, the shares have declined 66% over the past six months. The same analysis indicates the stock appears undervalued at current levels and highlights that Doximity maintains gross profit margins near 90% - one of more than a dozen tips noted for subscribers to the referenced analysis service.


Quarterly performance and analyst reactions

Doximity reported fiscal third-quarter results in which revenue and EBITDA outperformed both the company’s guidance and consensus estimates by $4.6 million and $7.9 million, respectively. The stronger-than-expected quarterly metrics have prompted a variety of responses from equity analysts:

  • Canaccord Genuity upgraded Doximity to a Buy rating on valuation grounds, while lowering its price target from $48.00 to $34.00.
  • Piper Sandler raised its price target to $42.00 and maintained an Overweight rating, citing an assessment of Doximity’s suite of AI tools.
  • Mizuho trimmed its price target to $34.00 but kept a Neutral rating, noting delays in pharmaceutical marketing budgets as a factor.
  • BMO Capital reduced its price target to $25.00, flagging near-term headwinds while acknowledging that the quarter beat expectations.

Takeaway

The insider sale executed under an automatic trading plan was accompanied by share-class conversion and option exercises by Siddharth. The company’s recent quarterly outperformance coexists with a steep six-month stock decline and mixed analyst assessments, reflecting divergent views on near-term headwinds and valuation. The data presented here is limited to the reported transactions, market prices, quarterly beat amounts and the stated analyst actions.


Risks

  • Shares trading near the 52-week low and down 66% over six months present market-price risk for investors - impacts equity investors and capital markets.
  • Analyst divergence on price targets and ratings indicates uncertainty about near-term valuation and demand drivers - impacts sell-side research and investor sentiment.
  • Delays in pharmaceutical marketing budgets, as cited by Mizuho, create revenue risk for Doximity’s business tied to pharmaceutical advertising and marketing - impacts healthcare marketing spend and related technology providers.

More from Insider Trading

Palladyne AI CFO Disposes $57,749 in Stock; Company Posts Strong Revenue Growth but Remains Loss-Making Mar 12, 2026 Palladyne AI Chief Legal Officer Disposes $51,355 in Stock; Executive Also Receives RSUs Mar 12, 2026 Figure Technology Director Disposes $7.29M in Class A Shares Mar 12, 2026 Stewart Information Director Adds 1,000 Shares in Mid-March Trades Mar 12, 2026 Reliance Global Group CFO Disposes of Shares Worth About $79K Mar 12, 2026